270 related articles for article (PubMed ID: 15354183)
1. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.
Giuffrida A; Leweke FM; Gerth CW; Schreiber D; Koethe D; Faulhaber J; Klosterkötter J; Piomelli D
Neuropsychopharmacology; 2004 Nov; 29(11):2108-14. PubMed ID: 15354183
[TBL] [Abstract][Full Text] [Related]
2. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.
Leweke FM; Giuffrida A; Koethe D; Schreiber D; Nolden BM; Kranaster L; Neatby MA; Schneider M; Gerth CW; Hellmich M; Klosterkötter J; Piomelli D
Schizophr Res; 2007 Aug; 94(1-3):29-36. PubMed ID: 17566707
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms.
Morgan CJ; Page E; Schaefer C; Chatten K; Manocha A; Gulati S; Curran HV; Brandner B; Leweke FM
Br J Psychiatry; 2013 May; 202(5):381-2. PubMed ID: 23580381
[TBL] [Abstract][Full Text] [Related]
4. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.
Koethe D; Giuffrida A; Schreiber D; Hellmich M; Schultze-Lutter F; Ruhrmann S; Klosterkötter J; Piomelli D; Leweke FM
Br J Psychiatry; 2009 Apr; 194(4):371-2. PubMed ID: 19336792
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy.
Romigi A; Bari M; Placidi F; Marciani MG; Malaponti M; Torelli F; Izzi F; Prosperetti C; Zannino S; Corte F; Chiaramonte C; Maccarrone M
Epilepsia; 2010 May; 51(5):768-72. PubMed ID: 19817812
[TBL] [Abstract][Full Text] [Related]
6. Elevated endogenous cannabinoids in schizophrenia.
Leweke FM; Giuffrida A; Wurster U; Emrich HM; Piomelli D
Neuroreport; 1999 Jun; 10(8):1665-9. PubMed ID: 10501554
[TBL] [Abstract][Full Text] [Related]
7. Association of anandamide with altered binocular depth inversion illusion in schizophrenia.
Reuter AR; Bumb JM; Mueller JK; Rohleder C; Pahlisch F; Hanke F; Arens E; Leweke FM; Koethe D; Schwarz E
World J Biol Psychiatry; 2017 Sep; 18(6):483-488. PubMed ID: 27734750
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Leweke FM; Piomelli D; Pahlisch F; Muhl D; Gerth CW; Hoyer C; Klosterkötter J; Hellmich M; Koethe D
Transl Psychiatry; 2012 Mar; 2(3):e94. PubMed ID: 22832859
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients.
Pisani V; Moschella V; Bari M; Fezza F; Galati S; Bernardi G; Stanzione P; Pisani A; Maccarrone M
Mov Disord; 2010 May; 25(7):920-4. PubMed ID: 20461809
[TBL] [Abstract][Full Text] [Related]
10. Familial abnormalities of endocannabinoid signaling in schizophrenia.
Koethe D; Pahlisch F; Hellmich M; Rohleder C; Mueller JK; Meyer-Lindenberg A; Torrey EF; Piomelli D; Leweke FM
World J Biol Psychiatry; 2019 Feb; 20(2):117-125. PubMed ID: 29521179
[TBL] [Abstract][Full Text] [Related]
11. Anandamide dysfunction in prodromal and established psychosis.
Leweke FM
Curr Pharm Des; 2012; 18(32):5188-93. PubMed ID: 22716147
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
D'Argenio G; Valenti M; Scaglione G; Cosenza V; Sorrentini I; Di Marzo V
FASEB J; 2006 Mar; 20(3):568-70. PubMed ID: 16403786
[TBL] [Abstract][Full Text] [Related]
13. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.
Thiemann G; van der Stelt M; Petrosino S; Molleman A; Di Marzo V; Hasenöhrl RU
Behav Brain Res; 2008 Mar; 187(2):289-96. PubMed ID: 17988751
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.
Tzavara ET; Li DL; Moutsimilli L; Bisogno T; Di Marzo V; Phebus LA; Nomikos GG; Giros B
Biol Psychiatry; 2006 Mar; 59(6):508-15. PubMed ID: 16199010
[TBL] [Abstract][Full Text] [Related]
15. Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.
Minichino A; Senior M; Brondino N; Zhang SH; Godwlewska BR; Burnet PWJ; Cipriani A; Lennox BR
JAMA Psychiatry; 2019 Sep; 76(9):914-923. PubMed ID: 31166595
[TBL] [Abstract][Full Text] [Related]
16. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia.
Ujike H; Morita Y
J Pharmacol Sci; 2004 Dec; 96(4):376-81. PubMed ID: 15613777
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Sarchielli P; Pini LA; Coppola F; Rossi C; Baldi A; Mancini ML; Calabresi P
Neuropsychopharmacology; 2007 Jun; 32(6):1384-90. PubMed ID: 17119542
[TBL] [Abstract][Full Text] [Related]
18. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
[TBL] [Abstract][Full Text] [Related]
19. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects.
Muguruza C; Lehtonen M; Aaltonen N; Morentin B; Meana JJ; Callado LF
Schizophr Res; 2013 Aug; 148(1-3):145-50. PubMed ID: 23800614
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation.
Wang H; Xie H; Sun X; Kingsley PJ; Marnett LJ; Cravatt BF; Dey SK
Prostaglandins Other Lipid Mediat; 2007 Feb; 83(1-2):62-74. PubMed ID: 17259073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
